Asambly Chemicals Co. Ltd.

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
News
Home ProductsActive Pharmaceutical Ingredients

Ranolazine Active Pharmaceutical Ingredients CAS 142387 99 3

I'm Online Chat Now

Ranolazine Active Pharmaceutical Ingredients CAS 142387 99 3

China Ranolazine Active Pharmaceutical Ingredients CAS 142387 99 3 supplier

Large Image :  Ranolazine Active Pharmaceutical Ingredients CAS 142387 99 3

Product Details:

Place of Origin: China
Certification: GMP condition

Payment & Shipping Terms:

Minimum Order Quantity: 1KG
Packaging Details: Drum
Contact Now
Detailed Product Description
Name: Ranolazine CAS: 142387-99-3
Molecular Formula: C24H33N3O4
High Light:

668270 12 0

,

1377049 84 7

Ranolazine CAS . 142387-99-3 GMP DMF support

 

Name : Ranolazine

 

Chemical Name : rac Ranolazine Active Pharmaceutical Ingredients CAS 142387 99 3 0- ( 2 , 6 - Ranolazine Active Pharmaceutical Ingredients CAS 142387 99 3 0dimethylphenyl ) - 2 - { 4 - [ 2 - hydroxy - 3 - ( 2 - Ranolazine Active Pharmaceutical Ingredients CAS 142387 99 3 0methoxyphenoxy ) propyl ] piperazin - 1 - yl } acetamide 

 

CAS No . : 142387-99-3

 

Molecular Formula : C24H33N3O4

 

Molecular Weight : 427.54

 

Description : 

 

Ranolazine is the active pharmaceutical ingredient (API) of branded drug Ranexa which is used as an antiangina. medication to treat chronic angina (chest pain). It was first approved in 2006 by FDA and is now marketed by Gilead Sciences Inc.  It should be used together with other drugs such as amlodipine, beta-blockers or nitrates. It does not depend upon reductions in heart rate or blood pressure and is the first new anti-anginal in over 20 years.

 

Syntex Inc. originally began the ranolazine development in 1985 and completed 61 studies till1994. Afterwards, Phase II studies were done but it was found that the formulation did not result in adequate plasma concentrations of drug. Then the sustained-release ( SR ) formulation was created.

 

In 1996, CV Therapeutics got the North American and European rights to ranolazine from Syntex accquired by Roche in 1994 and then in 2006, accquired the remaining worldwide rights to ranolazine. In 2008 Menarini accquired exclusively rights for ranolazine in Europe and some other countries from CV and then Gilead accuired CV in 2009. Gilead expanded the partnership with Menarini to include additional countries in 2013.

 

The drug might be protected by patents in some courtires or areas. We only sell it to non patent protected countries or areas. The sale to patent protection countries and areas is only for R & D purpose. The buyers should take all responsiblity of patent status in his countries or areas.

 

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations

Contact Details
Asambly Chemicals Co. Ltd.

Contact Person: MAO Xiaolong

Send your inquiry directly to us (0 / 3000)